Literature DB >> 28271260

Clinicopathological Characteristics of Hepatocellular Carcinoma with Microscopic Portal Venous Invasion and the Role of Anatomical Liver Resection in These Cases.

Shingo Shimada1, Toshiya Kamiyama2, Hideki Yokoo2, Tatsuya Orimo2, Kenji Wakayama2, Takahiro Einama2, Tatsuhiko Kakisaka3, Hirofumi Kamachi2, Akinobu Taketomi2.   

Abstract

BACKGROUND: The aims of this study were to investigate predictive factors for microscopic portal venous invasion (mPVI) in hepatocellular carcinoma (HCC) and whether anatomical liver resection (ALR) was useful in such cases.
METHODS: We analyzed 852 patients with HCC without macroscopic portal venous invasion who were treated at our hospital between January 1990 and May 2014. These patients were stratified into a microscopic portal venous invasion group (mPVI group; n = 153) and non-microscopic portal venous invasion group (NmPVI group; n = 699).
RESULTS: PIVKA-II ≥100 mAU/ml, a tumor size ≥5 cm, a confluent lesion, and poor differentiation were found to be independent risk factors for mPVI. Among the mPVI group who had single HCC under 5 cm, serum albumin level <4.0 g/dl, PIVKA-II ≥100 mAU/ml, a positive surgical margin, and non-ALR (NALR) were independent unfavorable prognostic factors for overall survival (OS). PIVKA-II ≥100 mAU/ml, a positive surgical margin and NALR were independent unfavorable prognostic factors for relapse-free survival (RFS). ALR was significantly favorable factor for both OS and RFS of the mPVI group who had single HCC under 5 cm.
CONCLUSIONS: Even if no portal venous invasion is detectable in HCC patients preoperatively, a PIVKA-II ≥100 mAU/ml, tumor size ≥5 cm, and a confluent lesion indicate a high risk of mPVI. ALR should be considered for the patients with these characteristics because it is a favorable prognostic factor in these cases with mPVI.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28271260     DOI: 10.1007/s00268-017-3964-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  36 in total

1.  Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection.

Authors:  Susumu Eguchi; Mitsuhisa Takatsuki; Masaaki Hidaka; Akihiko Soyama; Tetsuo Tomonaga; Izumi Muraoka; Takashi Kanematsu
Journal:  World J Surg       Date:  2010-05       Impact factor: 3.352

2.  Postoperative recurrence of hepatocellular carcinoma.

Authors:  T Nagao; S Inoue; F Yoshimi; M Sodeyama; Y Omori; T Mizuta; N Kawano; Y Morioka
Journal:  Ann Surg       Date:  1990-01       Impact factor: 12.969

3.  Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in single small HCC.

Authors:  K Kenmochi; S Sugihara; M Kojiro
Journal:  Liver       Date:  1987-02

4.  Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma.

Authors:  T J Tsai; G Y Chau; W Y Lui; S H Tsay; K L King; C C Loong; C Y Hsia; C W Wu
Journal:  Surgery       Date:  2000-06       Impact factor: 3.982

5.  Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma.

Authors:  T Matsumata; T Kanematsu; K Takenaka; Y Yoshida; T Nishizaki; K Sugimachi
Journal:  Hepatology       Date:  1989-03       Impact factor: 17.425

6.  The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin.

Authors:  Ken Shirabe; Shinji Itoh; Tomoharu Yoshizumi; Yuji Soejima; Akinobu Taketomi; Shin-Ichi Aishima; Yoshihiko Maehara
Journal:  J Surg Oncol       Date:  2007-03-01       Impact factor: 3.454

7.  Perioperative management of hepatic resection toward zero mortality and morbidity: analysis of 793 consecutive cases in a single institution.

Authors:  Toshiya Kamiyama; Kazuaki Nakanishi; Hideki Yokoo; Hirofumi Kamachi; Munenori Tahara; Kenichiro Yamashita; Masahiko Taniguchi; Tsuyoshi Shimamura; Michiaki Matsushita; Satoru Todo
Journal:  J Am Coll Surg       Date:  2010-08-08       Impact factor: 6.113

8.  Factors correlated with portal venous invasion by hepatocellular carcinoma: univariate and multivariate analyses of 232 resected cases without preoperative treatments.

Authors:  E Adachi; T Maeda; K Kajiyama; N Kinukawa; T Matsumata; K Sugimachi; M Tsuneyoshi
Journal:  Cancer       Date:  1996-05-15       Impact factor: 6.860

9.  Survival in liver transplant recipients with hepatitis B- or hepatitis C-associated hepatocellular carcinoma: the Chinese experience from 1999 to 2010.

Authors:  Zhenhua Hu; Jie Zhou; Haibo Wang; Min Zhang; Shaogang Li; Yuzhou Huang; Jian Wu; Zhiwei Li; Lin Zhou; Shusen Zheng
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

10.  Surgical outcomes of anatomical resection for solitary recurrent hepatocellular carcinoma.

Authors:  Yo-Ichi Yamashita; Daisuke Imai; Yuki Bekki; Kazuki Takeishi; Eiji Tsujita; Toru Ikegami; Tomoharu Yoshizumi; Tetsuo Ikeda; Ken Shirabe; Teruyoshi Ishida; Yoshihiko Maehara
Journal:  Anticancer Res       Date:  2014-08       Impact factor: 2.480

View more
  11 in total

1.  Prognoses and Clinicopathological Characteristics for Hepatocellular Carcinoma Originating from the Caudate Lobe After Surgery.

Authors:  Shingo Shimada; Toshiya Kamiyama; Hideki Yokoo; Tatsuya Orimo; Akihisa Nagatsu; Takanori Ohata; Hirofumi Kamachi; Akinobu Taketomi
Journal:  World J Surg       Date:  2019-04       Impact factor: 3.352

2.  CT Image-Based Texture Analysis to Predict Microvascular Invasion in Primary Hepatocellular Carcinoma.

Authors:  Yueming Li; Xuru Xu; Shuping Weng; Chuan Yan; Jianwei Chen; Rongping Ye
Journal:  J Digit Imaging       Date:  2020-09-23       Impact factor: 4.056

3.  Microscopic vascular invasion by hepatocellular carcinoma in liver transplant patients.

Authors:  Brian I Carr; Volkan Ince; Harika Gozukara Bag; Veysel Ersan; Sertac Usta; Sezai Yilmaz
Journal:  Clin Pract (Lond)       Date:  2020

4.  Preoperative color Doppler ultrasonography predicts early recurrence in AFP-positive hepatocellular carcinoma.

Authors:  Miao Chen; Duo Wang; Yuan Zhao; Dan-Mei Lu; Hong-Xue Li; Jun-Jie Liu; Hang Li
Journal:  Oncol Lett       Date:  2019-09-09       Impact factor: 2.967

5.  Clinical significance of glypican-3-positive circulating tumor cells of hepatocellular carcinoma patients: A prospective study.

Authors:  Michinori Hamaoka; Tsuyoshi Kobayashi; Yuka Tanaka; Hiroaki Mashima; Hideki Ohdan
Journal:  PLoS One       Date:  2019-05-29       Impact factor: 3.240

6.  Impact of Surgical Margin on the Prognosis of Early Hepatocellular Carcinoma (≤5 cm): A Propensity Score Matching Analysis.

Authors:  Han Wang; Hua Yu; You-Wen Qian; Zhen-Ying Cao; Meng-Chao Wu; Wen-Ming Cong
Journal:  Front Med (Lausanne)       Date:  2020-05-07

7.  Impact of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging on the prognosis of hepatocellular carcinoma after surgery.

Authors:  Shingo Shimada; Toshiya Kamiyama; Tatsuhiko Kakisaka; Tatsuya Orimo; Akihisa Nagatsu; Yoh Asahi; Yuzuru Sakamoto; Daisuke Abo; Hirofumi Kamachi; Akinobu Taketomi
Journal:  JGH Open       Date:  2020-10-30

8.  FXYD6 overexpression in HBV-related hepatocellular carcinoma with cirrhosis.

Authors:  Xiongfei Chen; Lishuang Ding; Deshuai Kong; Xiulei Zhao; Lili Liao; Yaomin Zhang; Fengshan Li; Ruhai Liu
Journal:  Open Life Sci       Date:  2020-04-20       Impact factor: 0.938

9.  Radiomics Analysis of Contrast-Enhanced CT for the Preoperative Prediction of Microvascular Invasion in Mass-Forming Intrahepatic Cholangiocarcinoma.

Authors:  Fei Xiang; Shumei Wei; Xingyu Liu; Xiaoyuan Liang; Lili Yang; Sheng Yan
Journal:  Front Oncol       Date:  2021-11-19       Impact factor: 6.244

10.  Sub-Classification of Cirrhosis Affects Surgical Outcomes for Early Hepatocellular Carcinoma Independent of Portal Hypertension.

Authors:  Er-Lei Zhang; Jiang Li; Jian Li; Wen-Qiang Wang; Jin Gu; Zhi-Yong Huang
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.